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In Alzheimer’s disease (AD), Amyloid β (Aβ) impairs synaptic function by inhibiting long-
term potentiation (LTP), and by facilitating long-term depression (LTD). There is now
evidence from AD models that Aβ provokes this shift toward synaptic depression by
triggering the access to and accumulation of PTEN in the postsynaptic terminal of
hippocampal neurons. Here we quantified the PTEN in 196,138 individual excitatory
dentate gyrus synapses from AD patients at different stages of the disease and from
controls with no neuropathological findings. We detected a gradual increase of synaptic
PTEN in AD brains as the disease progresses, in conjunction with a significant decrease
in synaptic density. The synapses that remain in symptomatic AD patients are more
likely to be smaller and exhibit fewer AMPA receptors (AMPARs). Hence, a high Aβ
load appears to strongly compromise human hippocampal synapses, as reflected by
an increase in PTEN, inducing a loss of AMPARs that may eventually provoke synaptic
failure and loss.
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INTRODUCTION
Alzheimer’s disease (AD) is the most common cause of dementia in western countries, and given
the increasing longevity of many populations worldwide, the social and economic impact of AD is
mounting (Frozza et al., 2018). Clinically, AD most often presents with the subtle onset of memory
loss and the inability to form new memories, followed by the slow progression of dementia over the
course of several years. In the brain, the dentate gyrus (DG) resists the formation of plaques, tangles,
and neurodegeneration until the later stages of AD, although changes regarding its dissociation
from other regions may contribute to the cognitive disturbances in AD, as might other intrinsic
alterations (Ohm, 2007). Granular cells in the DG receive excitatory synaptic inputs from the
medial and lateral entorhinal cortex (EC) via the perforant path (Woods et al., 2018). Inputs from
the EC to the DG play a role in pattern separation, a process that involves the storage of similar
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experiences using non-overlapping memory (Yassa and Stark,
2011) and that is involved in the initiation of memory retrieval
from the hippocampal CA3 (Lee and Kesner, 2004). Such
events become disrupted in the aging brain (Yassa et al., 2011),
and indeed, acute DG inactivation impairs memory encoding
(Kheirbek et al., 2013; Madroñal et al., 2016) and retrieval
(Tayler et al., 2013). Thus, DG networks are essential for the
encoding, retrieval, and discrimination of memories (Ohm, 2007;
Hainmueller and Bartos, 2020).
Because there is as yet no specific treatment available, the
management of AD is difficult and frustrating with a primary
focus on the long-term amelioration of associated behavioral
and neurological problems (McCall, 2013; Noroozian, 2016;
Cummings et al., 2018; Frozza et al., 2018; Sabbagh et al.,
2019). To develop effective therapies for AD, it is necessary to
fully understand the pathophysiological mechanisms that lead to
cognitive impairment in the early stages of this disorder. The
accumulation of Amyloid β peptide (Aβ) may initially impair
cognitive function, causing mild alterations to hippocampal
synaptic function (Selkoe, 2002; Palop and Mucke, 2010; Motta
et al., 2018; Tanaka et al., 2019) prior to the appearance of
synaptic loss and cell death (Selkoe, 2002; Cummings et al.,
2015). However, the exact molecular mechanisms that link Aβ
to synaptic and cognitive impairment are not fully understood,
although there is now growing evidence that Aβ triggers a
pathologically enhanced form of synaptic depression (Hsieh et al.,
2006; Knafo et al., 2016; Knafo and Esteban, 2017).
One protein strongly linked to Aβ-dependent synaptic
depression is PTEN (Phosphatase and Tensin Homolog Deleted
on Chromosome Ten). PTEN participates in NMDA-dependent
long-term depression (LTD) in the adult brain (Jurado et al.,
2010; Knafo et al., 2016; Sanchez-Puelles et al., 2020), and it
may mediate the synaptic plasticity that contributes to cognitive
processes and normal brain function (Takeuchi et al., 2013;
Hobert et al., 2014; Knafo et al., 2016; Knafo and Esteban,
2017; Wang et al., 2017; Sanchez-Puelles et al., 2020). We
previously showed that Aβ triggers the entry of PTEN into
the postsynaptic compartment, where it accumulates (Knafo
et al., 2016) and can interact with PDZ proteins, possibly PSD-
95 (Jurado et al., 2010; Knafo et al., 2016; Sanchez-Puelles
et al., 2020). The activity of PTEN at synapses provokes a
local downregulation of the PIP3 pathway, and eventually,
it triggers the endocytosis of α-amino-3-hydroxy-5-methyl-
4-isoxazole propionic acid receptors (AMPARs) that causes
synaptic depression (Arendt et al., 2010; Jurado et al., 2010; Knafo
et al., 2016).
This study aimed to validate the results obtained in AD
models and to precisely assess the PTEN and AMPAR that
can be found in hippocampal synapses. We also examined
the relationship between these parameters to the Aβ load,
as reflected by the intracellular and extracellular hippocampal
Aβ. As such, we scanned with a super-resolution confocal
microscopy preparations of the human hippocampal formation
immunostained for PSD-95 as a postsynaptic marker and for
PTEN. We analyzed the intensity of PTEN fluorescence within
each PSD-95 puncta. Doing so in thousands of puncta in patients
at different stages of AD indicated that there is significantly more
PTEN within PSD-95 puncta at advanced AD stages, while the
density of PSD-95 puncta diminishes. We isolated synaptosomes
from human hippocampal preparations and examined the levels
of the AMPAR subunit GluA1, witnessing a waning of synaptic
GluA1 in advanced AD cases. Our results suggest that AD
progression is associated with an increase in Aβ load and a loss
of excitatory synapses. The synapses remaining are likely to be
smaller, and they contain higher levels of PTEN and lower levels
of GluA1-containing AMPARs. These pathological alterations to
synapses probably trigger substantial changes in the connectivity
between the EC and the hippocampal formation, which may
produce cognitive impairment and dementia.
MATERIALS AND METHODS
All the experiments carried out in this study were performed
blind and each specimen was given a code that was not broken
until after the analysis had terminated.
Patient Selection
Neuropathological categorization was performed according to
the Braak and Braak classification adapted for paraffin sections
(Braak et al., 2006) (representative examples of sections for each
of the stages are shown in Figure 1). The samples from patients
were classified as controls (showing no neuropathological
findings or lesions), asymptomatic AD (Braak and Braak stage I–
III) or symptomatic AD (Braak and Braak stage IV–VI). Please
refer to Table 1 for the patient details and to Supplementary
Table 1 for details on the average age in each experiment.
Tissue Preparation
The whole hippocampus was collected at autopsy and cut into
7–12 mm thick blocks transverse to the long axis, maintaining
them at -80◦C until use. Subsequently, series of cryostat
sections (4 µm) were obtained at –20◦C (Leica CM3050s, Leica
Biosystems) and mounted on frozen gelatinized slides. The tissue
was fixed in 4% paraformaldehyde for 10 min at 4◦C and
processed for immunohistochemistry. This procedure allowed
10–12 different specimens to be processed in parallel. Staining
for phosphorylated tau (clone AT8) and β-amyloid (Aβ) were
performed on one series, DAPI staining was combined with PSD-
95 and PTEN on the next consecutive sections, and DAPI staining
combined with Thioflavin-S was performed on the following
consecutive sections.
Braak and Braak Classification
Paraffin sections were processed for immunohistochemistry
using the AT8 (Innogenetics, Ghent, BE) and Aβ (Dako,
Glostrup, DK) antibodies, both at a dilution of 1:50, the binding
of which was detected with EnVision+ System peroxidase (Dako,
Agilent Technologies, Barcelona, Spain). The immunoreaction
was visualized with diaminobenzidine and H2O2, and the
sections were counterstained lightly with haematoxylin (bar = 50
µm). The patients’ AD pathology was categorized using the
Braak and Braak scale adapted to immunohistochemistry on
paraffin sections.
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FIGURE 1 | Patient classification and Aβ measurement. (A) Representative changes in pathological Alzheimer’s disease revealed with anti-phosphorylated tau (clone
AT8) and Aβ antibodies, categorized following the Braak and Braak nomenclature adapted for immunohistochemistry in paraffin sections: NFT II, III and IV indicate
neurofibrillary tangle pathology stages II, III and IV; SP A, B and C refer to senile plaque burden stages A, B and C. The upper row mainly focuses on the NFT
pathology, whereas the middle row on the tau pathology surrounding amyloid deposits. The lower row shows the morphology of diffuse plaques on the left and the
core plaques on the right, with a mixture of them in the central image. (B) The age range (Top) and gender of the patients in the current cohort (Bottom). (C) Left, the
hippocampal formation was fractionated into the cytosolic (C) and membrane fractions (M), testing the efficacy of this separation in western blots probed for the
AMPAR subunit as a marker of the membrane fraction marker. Right, Aβ levels were determined by ELISA [pg/µg protein] in the cytosolic and membrane fractions. N
is the number of patients, and the data are presented as the average ± SEM.
ELISA
We first verified that the cytosolic/membrane fraction had been
obtained correctly in western blots (Figure 1C), analyzing the
Aβ42 monomers with the Human Aβ42 ELISA Kit (Thermofisher
Scientific). The standard curve of the Aβ42 peptides was
obtained with serial dilutions of the standard peptides. The
standard peptide was included in the kit, and it was diluted in
“Reconstitution Buffer” (also included in the kit) according to
the volume marked on the label. For Aβ quantification, samples
were diluted with standard dilution buffer (supplied with the
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TABLE 1 | Patients classification, age, and post-mortem interval.
Classification Age (y) Gender Post-mortem
interval (h)
Braak and braak stage
Control 65 F 4 No pathological findings
Control 63 M 17 No pathological findings
Control 46 F 9 No pathological findings
Control 43 M 5 No pathological findings
Control 46 M 15 No pathological findings
Control 43 M 4 No pathological findings
Control 52 M 3 No pathological findings
Control 50 M 17 No pathological findings
Control 51 F 4 No pathological findings
Control 53 M 3 No pathological findings
Control 46 F 14 No pathological findings
Control 52 M 3 No pathological findings
Control 47 M 10 No pathological findings
Control 55 M 13 No pathological findings
Control 55 M 5 No pathological findings
Control 65 F 5 No pathological findings
Control 81 F 4 No pathological findings
Control 66 F 4 No pathological findings
Control 48 F 4 No pathological findings
Control 56 M 4 No pathological findings
Control 40 M 5 No pathological findings
Asymptomatic AD 78 M 7 Stage I
Asymptomatic AD 86 M 18 Stage I
Asymptomatic AD 79 M 5 Stage I
Asymptomatic AD 74 M 6 Stage I
Asymptomatic AD 76 M 4 Stage I
Asymptomatic AD 74 F 2 Stage I
Asymptomatic AD 72 M 8 Stage II
Asymptomatic AD 71 M 5 Stage II
Asymptomatic AD 67 M 7 Stage II
Asymptomatic AD 88 F 5 Stage II
Asymptomatic AD 83 M 18 Stage III
Asymptomatic AD 88 F 1 Stage III
Asymptomatic AD 64 M 4 Stage III
Asymptomatic AD 68 F 5 Stage III
Asymptomatic AD 77 F 3 Stage III
Asymptomatic AD 90 M 2 Stage III
Symptomatic AD 80 F 2 Stage IV
Symptomatic AD 82 M 5 Stage IV
Symptomatic AD 84 M 12 Stage IV
Symptomatic AD 74 M 4 Stage IV
Symptomatic AD 75 M 6 Stage IV
Symptomatic AD 77 M 19 Stage IV
Symptomatic AD 81 M 3 Stage IV
Symptomatic AD 79 M 4 Stage IV
Symptomatic AD 78 M 16 Stage V
Symptomatic AD 78 M 9 Stage V
Symptomatic AD 85 F 16 Stage V
Symptomatic AD 74 F 5 Stage V
Symptomatic AD 77 F 3 Stage VI
kit) to keep the concentration within the detectable range (1–
100 pg/ml). After the addition of the stop solution, the 96-well
plate was read at 450 nm, and the sample concentration was
calculated from a standard curve prepared using purified Aβ of
various concentrations.
Thioflavin-S Staining
After fixing, the sections were dehydrated through a series of
ethyl alcohol solutions (70, 80, 95, and 100%, 2 min in each) and
then stained with 1% Thioflavin S for 30–60 min. The sections
were then rehydrated and dipped in DAPI. After staining,
the sections were covered with ProLong Gold (Thermo Fisher
Scientific) and coverslipped.
Immunofluorescence
Fixed sections were permeabilized with 0.1% Triton X-100
for 30 min and non-specific antibody binding was avoided
by incubating at room temperature (RT) for 2 h in blocking
solution (5% horse serum, 0.1% Triton X-100 in PBS). Dual
immunohistochemistry was then performed sequentially to study
PSD-95 (1:250 in blocking solution: D74D3, Cell Signaling
Technology) and PTEN (1:200 in blocking solution: AMB-2052,
Cascade BioSciences) using primary monoclonal antibodies.
Antibody binding was detected for 30 min at 37◦C with
their corresponding secondary antibodies: donkey anti-mouse
conjugated to Alexa Fluor 350 (1:1000 in blocking solution:
Invitrogen) and goat anti-rabbit conjugated to Alexa Fluor
594 (1:1000 in blocking solution: Life Technologies). After
staining, the sections were mounted with ProLong Gold (Thermo




Entire DAPI/Thioflavin S-stained sections were scanned using a
3D Scan Pannoramic Histech scanner (3D Histech Kft. Budapest,
Hungary) at a resolution of 0.23 µm per pixel. Images were
analyzed using Pannoramic Viewer 1.15.2 SP2 RTM (3D Histech
kft.) or Histoquant (3D Histech kft.) software, which provides
a detailed morphometric analysis with precise measurements of
different histological parameters at high resolution (Figure 2).
Plaques were detected automatically, and the number of plaques
per section and the area of each plaque was evaluated.
PSD-95 and PTEN
Super-resolution images of immunostained sections were
obtained by laser-scanning confocal microscopy (Zeiss LSM
880, Carl Zeiss) over 10–20 fields in the molecular layer of
the DG using identical acquisition parameters for all the
sections. Images were acquired on a Zeiss LSM 880 Airyscan
through an oil immersion 63× Plan-Apochromat objective
(N.A.: 1.4) with a final spatial resolution of 0.075 microns/pixel.
Laser excitation wavelengths were 405, 488, and 561 nm, and
fluorescent emission was collected in all cases through a 1 Airy
unit pinhole using selective 410–495 nm, 495–585 nm, and
585–733 nm spectra windows, respectively. Subsequently, 16 bit
images were generated with a maximal sampling size according
to the configuration of the optics. Quantification was performed
with Imaris software (version 9.6, Bitplane AG), building three
channels for PSD-95, PTEN, and DAPI. PSD-95 puncta (single
dots) were identified with the built-in spot detection algorithm
in Imaris, considering spots of different sizes and using local
background subtraction. To follow a rigorous method for all
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FIGURE 2 | Plaque detection in AD samples. (A) A slide scanner image (×5) of a DAPI-stained section (stage II) containing the hippocampal formation: Sub,
Subiculum; Ent, Entorhinal Cortex; DG, Dentate Gyrus; LV, Lateral Ventricle; CA1-3, Cornu Ammonis; FuG, Fusiform Gyrus. (B) A confocal image (×10) of a section
(stage V) containing mainly the dentate gyrus stained with DAPI (blue) and Thioflavin-S to detect the Aβ plaques (green): DG, Dentate Gyrus; H, Hilus. (C) High
magnification image (×40) of the dentate gyrus (stage V) where small Aβ aggregates can be seen in the granule cell layer (GCL, green) and an extensive Aβ plaque is
seen in the molecular layer (ML). (D) Left, Part of a section scanned with a slide scanner (×10) with Aβ plaques. Right, automatic detection of plaques, used to
calculate the plaque density and the area occupied by plaques. (E,F) A bar graph showing the plaque density and the area occupied by plaque. N is the number of
patients, and the data are presented as the average ± SEM. The scale bar in all the images is 50 µm.
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samples and to avoid possible artifacts in the quantification,
the average diameter of the spot was established as 0.3 µm for
the entire process and the same threshold levels were used for
all the sections. The algorithm yielded the sum of the PTEN
fluorescence intensity in each PSD95 spots, as well as the
individual spot sizes.
Tissue Fractionation Into Cytosolic and
Membrane Fractions
The tissue was placed in TBS [140 mM NaCl, 3 mM KCl, 25 mM
Tris-HCl (PH 4.7), and 5 mM EDTA] containing a cocktail
of proteases to avoid protein degradation and homogenized
in a Dounce Homogenizer. Subsequently, the homogenate at
50,000 rpm was centrifuged for 1 h at 4◦C (Coulter Optima
L-90K Ultracentrifugue, Beckman), separating the sample into
two fractions: the supernatant containing the fraction of soluble
proteins; and the pellet. The pellet was resuspended in 2% SDS
and centrifuged again at 4◦C for 30 min at 14,000 g (SorvallTM
LegendTM Micro 21R Microcentrifuge, ThermoScientific). The
supernatant from this latter centrifugation corresponds to the
fraction of membrane associated proteins.
Synaptosomal Preparation
We homogenized human hippocampal tissue in buffer A
(0.32 mM sucrose, 1 mM MgCl2, 0.5 mM CaCl2, 1 mM NaHCO3,
protease inhibitors) and centrifuged it at 1,400 g for 10 min
to obtain the supernatant (S1) and pellet (P1). P1 was then
homogenized in buffer A and centrifuged at 700 g for 10 min,
combining the resulting supernatant with S1 and centrifuging
these again at 13,800 g for 10 min. The supernatant obtained
(S2) was further centrifuged at 100,000 g for 1 h and the
resulting supernatant (S3) constituted the cytosolic fraction. The
resulting pellet was resuspended in buffer B (0.32 mM sucrose,
1 mM NaHCO3, 1 mM EGTA, 1 mM dithiothreitol, protease
inhibitors) and it represents the crude synaptosomal fraction
used for analysis.
Western Blotting
The lysates were collected and centrifuged at 13,000 rpm for
5 min at 4◦C, and the protein in the supernatants was quantified
using the BCA protein assay (Pierce, 23227) and compared
to bovine serum albumin (BSA) standards. Equal amounts of
total protein was prepared in 4× sample loading buffer and
boiled at 95◦C for 5 min immediately before electrophoresis.
Proteins (10 µg per lane) were separated according to their
molecular weight by SDS-PAGE in a Mini PROTEAN Tetra Cell
Vertical Electrophoresis system (Bio-Rad) and in 1× running
buffer [25 mM Tris (pH 8.3), 192 mM glycine, 0.1% SDS in
dH2O]. Following electrophoresis, the proteins were transferred
to a PVDF membrane (pore size 0.45 µm: Amersham Hybond,
10600023) in the Mini Trans-Blot Cell transfer system (Bio-Rad)
and in 1× transfer buffer [25 mM Tris (pH 7.6), 192 mM glycine,
20% methanol in dH2O] for 90 min at 400 mA. The membrane
was then stained with Ponceau S (Sigma Aldrich, P3504) to
confirm the successful transfer of the proteins. Non-specific
binding was blocked by incubation with 5% milk in TBS-T for
1 h at RT, and after washing the membranes, they were incubated
for 24 h at 4◦C with an antibodies against GluA1 (AMPAR
subunit) (1:1,000, Rabbit: ab31232, Abcam) or PTEN (1:1,000,
Rabbit, Cell Signaling Technology 9559L). The membranes were
then incubated with the secondary antibodies for 1 h at RT
(1:2000, HRP-conjugated anti-rabbit IgG: #7074; Cell Signaling
Technology) and the immunocomplexes were visualized with
a chemiluminescent agent (Immobilion R© Forte Western HRP
Substrate, Milipore). The anti-actin antibody (1: 1,000, Rabbit
Cell Signaling Technology, 4970S) was used as a protein loading
control. The membranes were again washed as described above
and the antibodies bound to their target proteins were detected
by enhanced chemiluminescence (Luminata Forte Western HRP
Substrate, Millipore, MIWBLUF0100) in a MyECL Imager
(Thermo Fisher Scientific), quantifying them by densitometry
using the Quantity One software (Bio-Rad).
RESULTS
Here we studied post-mortem hippocampal tissue from a total
of 50 patients that were classified according to the Braak and
Braak scale, staining brain sections with antibodies against
phosphorylated tau (p-tau) and Aβ (Figure 1A). According to
their clinical records and pathological classification, 16 patients
had mild-to-moderate AD pathology but with no sign of
cognitive impairment (asymptomatic, Braak and Braak stages
I–III: further divided into stage I and stage II/III), and 13
had a more advanced pathology involving AD-related cognitive
impairment (symptomatic, Braak and Braak stage IV–V). In
addition, tissue from 21 younger healthy individuals was used
as a control (No pathological findings). The age and gender
distribution was similar for the AD patients of different pathology
states (Figure 1B), and the range of the post-mortem intervals
was also similar among the groups (Table 1).
The Hippocampal Aβ Load Changes With
AD Stage
The recruitment of PTEN to the postsynaptic compartment
in rodent primary neurons is mediated by the Aβ (Knafo
et al., 2016) generated through the proteolytic processing of
the membrane-bound amyloid precursor protein (APP) (Bayer
et al., 2001). Intracellular Aβ interacts with the membrane to
provoke synaptic dysfunction, or alternatively, it is secreted into
the extracellular space (LaFerla et al., 2007). It has been previously
reported that Aβ triggers the entry of PTEN to the postsynaptic
compartment (Knafo et al., 2016). To characterize the Aβ load
in the hippocampal tissue, and the forms of Aβ appearing in
each stage of AD, we first separated the samples into cytosolic
and the membrane-bound fractions (Figure 1C), quantifying the
Aβ(1−42) monomers in each by ELISA. We found more cytosolic
and membrane Aβ(1−42) in tissue from patients at stages II–III
(late asymptomatic AD) than in that from the controls. However,
these values did not increase significantly in the tissue from
patients at later stages of dementia, stages IV–VI (Figure 1C).
The intracellular accumulation of Aβ may lead to neuronal
death and lysis, releasing Aβ into the extracellular space
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(LaFerla et al., 1997; D’andrea et al., 2001) where it can
accumulate and oligomerize to ultimately form plaques
(LaFerla et al., 1997; D’andrea et al., 2001). To quantify the Aβ
aggregated into plaques, we stained fixed hippocampal slices with
Thioflavin-S and scanned the entire sections at high resolution
with a slide scanner (Figures 2A–C). After controlled automatic
delineation of the Aβ plaque borders (Figure 2D), we quantified
the plaque density and the proportion of the area occupied
by plaques in each of the sections, witnessing an increase
in the plaque density as the disease progressed (Figure 2E).
As expected, plaques occupied a negligible proportion of the
neuropil in healthy controls, as well as at early stages of AD
clinically defined as asymptomatic (stages I–III). However, the
proportion of plaques increased significantly as the disease
advanced (Figure 2F), although even in the sections from
advanced-stage patients (IV–VI, symptomatic AD), the plaques
only occupied a maximum of 1.7% of the hippocampal neuropil
(Figure 2F). This finding is consistent with data from transgenic
mice bearing two familial AD mutations (APP/PS1) in which
plaques occupy a maximum of 5% of the hippocampal neuropil
(Knafo et al., 2009a,b; Merino-Serrais et al., 2011). Hence,
while soluble Aβ reaches maximal values in late asymptomatic
AD stages, the Aβ in plaques accumulates maximally at late
symptomatic AD stages.
High PTEN Levels in Symptomatic AD
Synapses
When recombinant PTEN expressed by dissociated hippocampal
neurons is exposed to high concentrations of synthetic Aβ(1−42)
it is immediately trafficked to the postsynaptic compartment
(Knafo et al., 2016). Upon its recruitment to spines, PTEN
interacts with PSD-95 and it induces the endocytosis of
AMAPRs, resulting in synaptic depression (Jurado et al., 2010).
To determine if the hippocampal synapses of AD patients
undergo such changes, we quantified the PTEN in individual
human excitatory synapses in the molecular layer of the DG
(Figures 3A,B). Hippocampal sections were subjected to dual
immunofluorescence for PTEN and PSD-95, the latter not only
interacting directly with PTEN but also serving as a marker of
excitatory synapses (Figures 3A,B). After scanning the sections
at high magnification (×63) with a super-resolution confocal
microscope (10–20 areas per patient), we used Imaris software
to detect approximately 200,000 individual PSD-95 puncta
(Figure 3B). We extracted the PTEN intensity within each puncta
as a measure of the amount of PTEN within the postsynaptic
compartment, and crucially, there was a gradual increase in
synaptic PTEN as AD pathology advanced (Figures 3C,D).
A frequency distribution analysis showed that PSD-95 puncta
from patients with an advanced AD pathology were more likely to
contain higher levels of PTEN and less likely to have lower levels
of PTEN than control puncta (Figure 3E).
Nonetheless, when the overall amount of PTEN in each
hippocampal preparation was measured in western blots,
significant differences could not be detected among the groups
(Figure 3F). Similarly, when the PTEN fluorescence intensity was
measured in individual DG nuclei (a total of 940 nuclei) we again
failed to detect changes related to AD (Figures 3G,H), suggesting
that the increase in PTEN levels is specific to synapses. These
findings confirmed previous observations in cell models of AD
in which a high Aβ load was linked to the specific recruitment of
PTEN to the postsynaptic compartment (Knafo et al., 2016).
AD Synapses Contain Fewer GluA1
Subunit-Containing AMPARs
A possible link between PTEN activity in synapses and cognitive
deterioration in AD is the ability of PTEN to modulate the
amount of AMPARs in the synapse. Indeed, PTEN regulates the
number of synaptic AMPARs (Yang et al., 2014) through the PIP3
pathway (Jurado et al., 2010; Knafo et al., 2016; Sanchez-Puelles
et al., 2020), which controls AMPAR trafficking (Qin et al., 2005)
and synaptic localization (Arendt et al., 2010) in hippocampal
neurons. AMPARs mediate excitatory transmission and maintain
cognitive function (Knafo et al., 2012). Overexpression of PTEN
leads to both cognitive impairment, impaired basal synaptic
transmission, and deficits in LTP (Long Term Potentiation)
(Sanchez-Puelles et al., 2020). Apart from delivering PTEN to
synapses, Aβ also triggers AMPAR endocytosis and facilitates
LTD (Chang et al., 2006; Hsieh et al., 2006; Gu et al., 2009;
Spires-Jones and Knafo, 2012; Knafo et al., 2016; Reinders et al.,
2016). Therefore, we hypothesized that synapses affected by AD
pathology would contain fewer AMPARs and we tested this
hypothesis in crude synaptosomal preparations isolated from
human hippocampal tissue, quantifying the GluA1 synaptic
AMPAR subunit in western blots. We first confirmed that
our synaptosomal fractionation contained a significantly higher
level of GluA1 compared with the initial lysate, implying a
suitable fractionation (Figure 4A, top). We observed an apparent
reduction in synaptic GluA1 that decreased gradually as the
disease progressed (Figure 4A, bottom and Supplementary
Figure 1). Studies on synaptic plasticity have stimulated ideas
of an essential overlap between molecular pathways involved in
LTD and synaptic shrinkage and/or pruning (Zhou et al., 2004;
Shinoda et al., 2010; Piochon et al., 2016). To determine whether
the size and the density of hippocampal synapses are affected in
AD patients, we quantified the density and size of PSD-95 puncta
in our preparations using Imaris software. When the frequency
distributions of PSD-95 puncta diameter were analyzed there
was an apparent increase in small puncta frequency (<0.35 µm:
Figures 4B,C) but crucially, a reduction in PSD-95 puncta
density was observed in patients with advanced symptomatic AD
that suggested they had a lower synaptic density (Figure 4D).
Together, these findings suggest there are fewer synapses in the
hippocampus of advanced AD patients, which are more likely to
be smaller and contain fewer AMPARs.
DISCUSSION
Understanding the molecular pathways through which the
various pathological alterations in AD compromise synaptic
function and potentially cause the clinical symptoms has been
a long-standing goal in AD research. Testing such pathways
in mouse and cell models that mimic various aspects of
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FIGURE 3 | Synaptic PTEN levels are enhanced in AD patients. (A) Tile-scanned confocal images (×10) of the hippocampal formation stained for PTEN (red) and
PSD-95 (green): DG, Dentate Gyrus; CA1-3, Cornu Ammonis. (B) Top, High magnification super-resolution images (63×) showing PSD-95 puncta (green) and PTEN
(red) at different stages. Bottom, Detection of PSD-95 puncta with Imaris software. (C) Heat map showing the average relative PTEN levels (normalized to controls) in
10 high-resolution confocal fields per patient. (D) A bar graph depicting the relative synaptic PTEN in each group of patients. N is the number of patients, and the
P-values were determined by One Way ANOVA followed by Tukey’s multiple comparisons test. (E) Frequency distribution of the PTEN in individual PSD-95 puncta.
(F) The total amount of PTEN in brain lysates was determined in western blots. Inset, a representative example of a blot at different stages. N is the number of
patients and the P-values were determined by One Way ANOVA. (G) Left, A confocal image (×40) of part of the dentate gyrus showing the nuclei stained with DAPI.
Middle, The detection of nuclei to determine the amount of nuclear PTEN. Right, The pixels outside the nuclear areas were set to zero to observe only nuclear PTEN
(red). (H) A bar graph depicting the relative nuclear PTEN in each group of patients. N is the number of patients and the P-value was determined by One Way ANOVA.
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FIGURE 4 | Synaptic GluA1, size and density. (A) Left-top, Hippocampal homogenates (H) were fractionated into crude synaptosomes (S), and the efficacy of
fractionation was tested in western blots probed for the GluA1 AMPAR subunit as a synaptic marker. Left-bottom, A western blot showing the PTEN in
synaptosomes, using actin as a loading control. Right, The average GluA1 in synaptosomes was determined in western blots. (B) Frequency size distribution of the
PSD-95 puncta. (C) Bar graph showing the proportion (%) of small PSD-95 in each group. (D) Bar graph showing the density of PSD-95 puncta. In all the graphs, N
is the number of patients and the data are presented as average ± SEM. P-values were determined by One Way ANOVA followed by Tukey’s multiple comparisons
test.
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this pathology aids this effort. As such, we now know from
cell and animal models that PTEN activity is required for
NMDAR-dependent LTD and that Aβ facilitates this type of
plasticity (Wang et al., 2006; Jurado et al., 2010; Sperow
et al., 2012; Knafo et al., 2016; Knafo and Esteban, 2017;
Sanchez-Puelles et al., 2020), establishing a potential link
between PTEN and AD. One possible pathological mechanism
in AD starts with Aβ overload, which leads to aberrant PTEN
recruitment to spines and affecting its interactions with the
postsynaptic scaffolding molecule PSD-95 in synapses, eventually
triggering the endocytosis of AMPARs. These new insights
indicate that this PTEN/PSD-95 interaction may represent a
new candidate target for the treatment of cognitive impairment
in AD. Indeed, a peptide has been designed based on
PTEN’s C-terminal sequence that can block this PTEN/PSD-
95 interaction and it has been successfully tested in AD model
mice (Knafo et al., 2016). Subsequent studies showed that
derivatives of the original peptide are stable in plasma and
they are capable of crossing the blood-brain barrier in vitro
(Lalatsa et al., 2020). Nevertheless, before continuing to develop
therapies based on overcoming this pathological mechanism,
it is imperative to detect parallel pathological alterations in
diseased human brains.
Here we examined the levels of PTEN in a relatively large
number of individual excitatory hippocampal synapses from
AD patients at different stages of the disease and from healthy
controls. We found that AD hippocampal synapses at advanced,
symptomatic stages contain more PTEN, which is associated
with a lower density of synapses that are both smaller and have
fewer GluA1-containing AMPARs. These pathological changes
occur in parallel to the accumulation of Aβ first intracellularly
and then extracellularly in plaques. Previous studies in cellular
AD models suggest a clear cause-effect relationship between
Aβ accumulation and PTEN recruitment to spines, and they
confirm that blocking PTEN activity, either by inhibiting its
catalytic activity or by preventing its interaction with PDZ
proteins at synapses (e.g., PSD-95) can prevent the exaggerated
synaptic depression and cognitive malfunctions typical of
AD models. Our finding regarding the higher proportion of
smaller PSD95 puncta follows a recent EM study on the
hippocampal CA1 region that used a three-dimensional analysis
of synapses and showed that AD synapses are slightly smaller
than controls (Montero-Crespo et al., 2021). Other studies
in the hippocampus (dentate gyrus and CA1) of transgenic
mice revealed an increase in the proportion of small spines
or decreased proportion of large spines (Knafo et al., 2009a;
Merino-Serrais et al., 2011), in accordance with the current
results. Combining these findings with the present study on
human AD hippocampal preparations, we now propose a model
describing the cascade of events occurring during AD disease
progression (Figure 5).
According to this model, healthy synapses are exposed to
negligible levels of Aβ and thus, PTEN mainly concentrates
outside the synapses. When Aβ starts to accumulate
intracellularly (some of it bound to cell membranes) it
triggers the entry of PTEN into spines. This entry of PTEN
requires its interaction with domains 1–2 of PSD-95 through its
FIGURE 5 | Phosphatase and Tensin Homolog Deleted on Chromosome Ten
(PTEN) at AD Synapses provokes Long-Term Depression and synaptic loss.
Top: Healthy synapses exhibit basal synaptic transmission due to weak PTEN
activity. Middle: in response to Aβ, PTEN is recruited to the postsynaptic
membrane via PDZ-dependent interactions with PSD-95. The turnover of PIP3
by PTEN facilitates AMPAR endocytosis and removal from synapses. Bottom:
When Aβ is elevated, the sustained recruitment of PTEN at the postsynaptic
membrane leads to excessive removal of AMPARs, skewing synaptic plasticity
toward depression and producing chronic synaptic weakening, shrinkage and
loss. The cell death provoked by Aβ overload also contributes to synaptic loss.
C-terminal PDZ motif (Jurado et al., 2010), (Knafo et al., 2016).
The engagement of PTEN during Aβ overload leads to its
anchoring at the postsynaptic density of dendritic spines (Jurado
et al., 2010) and although the mechanism regulating this PDZ
interaction remains unknown, it appears to require NMDAR
activation. This enhancement of PTEN lipid phosphatase
activity within the spines drives AMPR endocytosis, thereby
depressing AMPAR-mediated synaptic responses, and the
resulting LTD leads to synaptic shrinkage and pruning. The
neurotoxicity provoked by intracellular Aβ induces cell lysis,
further enhancing synaptic loss. At advanced AD stages, the
hippocampus contains numerous plaques, and it may suffer
largescale neurodegeneration. The neurons that remain contain
fewer and weaker synapses, with elevated levels of PTEN, which
may continue to compromise the synapses.
It is important to note that AD is a complex disease with
multiple molecular events occurring in parallel. Thus, our model
may reflect only one of the pathways that can provoke cognitive
impairment and dementia, and other pathways may be altered
in different patients, producing similar devastating outcomes.
Nevertheless, our findings suggest that synaptic failure in AD is
induced by an excess of PTEN, which shapes and reorganizes
neural circuits in the hippocampal formation, making cognitive
activity in the brain sub-optimal.
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